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Abstract
Among the extra-intestinal manifestations of inflammatory bowel diseases, those involving the
lung are relatively rare. However, there is a wide array of such manifestations, spanning from
drug-related pathologies to airway disease, fistulas, granulomatous diseases, autoimmune and
thromboembolic disorders. Although infrequent, people dealing with inflammatory bowel
diseases must be aware of these conditions, sometimes life-threatening, to avoid further
impairment of the health status of the patients and to alleviate their symptoms by prompt
recognition and treatment.
© 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.stroenterologia ed Epatologia
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Inflammatory bowel diseases (IBD) may be complicated by
extra-intestinal manifestations (EIMs) in up to 40% of patients,
and almost every organ system may be affected.1–3 The
incidence of EIMs increases with the disease duration, and
their prevalence is estimated to be around 21–41%.4
The most important etiologic factors for EIMs in IBD are
thought to be the presence of circulant immunocomplexes
and complement's deposits.5 Moreover, an altered intestinal
barrier accounts for the entry of numerous unfiltered
alimentary antigens, digestive enzymes and bacteria that
may cause local and systemic inflammatory reactions.6
Although rare (up to 2003 only about 400 cases were de-
scribed in literature 4) a growing number of literature reports
suggest that pulmonary disease occurs in association with IBD
more frequently than previously recognized.4,7,8 The same
embryological origin of lung and gastrointestinal tract by
ancestral intestine may explain the association between lung
involvement and IBD, and it has been shown a decrease of
blood total IgA produced by mononucleate intestinal cells of
IBD patients,9 that may favor pulmonary involvement.
Compared to healthy controls, IBD patients show signif-
icantly decreased lung function tests, such as forced
expiratory volume in 1 s, inspiratory vital capacity, Tiffe-
neau value, and lung CO transfer capacity, more pronounced
during activity flares than during remission.10 These abnor-
malities are found in more than 50% of IBD patients, and are
not predicted by the smoking status.11 It has been hypoth-
esized that these alterations might be due to a high
superoxide anion production by alveolar macrophages.12
The present article will examine pulmonary diseases
associated with IBD.
2. Drug-related lung pathology
Although drug-related diseases are not “properly” IBD-
associated disease, since IBD patients use several drugs for
prolonged periods of time, it is not surprising that some of
these may also cause problems to the lungs; therefore, this
kind of pathology will be considered here, taking into
account that it can occur also in patients undergoing
immunosuppression or other diseases.
2.1. Sulphasalazine and mesalazine
These are commonly used drugs for long-term treatment of
IBD (especially ulcerative colitis, UC), and their side effects
may be dose-related or idiosyncratic, and should be
separated from the respiratory involvement occurring in
IBD and due to the underlying disease, although this is not
always possible.13 Literature data report more than 50 casesof lung pathology related to the use of these compounds,14
mostly due to interstitial disease,10,15,16 although eosino-
philic pleuritis 17 and eosinophilic pneumonia18 have also
been described. In most cases, symptoms appear after 2–
6 months from the drug's use, whereas in a few cases they
appear after some days or after many years.1 The most
common symptoms are dyspnea (76%), fever (68%), chest
pain (65%) and cough (22%).1 Usually, interruption of the
drug resolve the symptoms; rarely, these disappear decreas-
ing the drug's dosage.19
2.2. Azathioprine (AZA) and 6-Mercaptopurine(6-MP)
Pulmonary toxicity due to these drugs has been reported
infrequently in literature, although interstitial pneumoni-
tis,20 restrictive lung disease,21 Goodpasture-like syndrome
and pulmonary hemorrhage 22 have been described after use
of AZA and 6-MP. Infectious pneumonia is the most common
cause of pulmonary symptoms in IBD pts on immunosuppres-
sive therapy including AZA.20 However, in a series of over 100
IBD pts on AZA therapy, no episodes of pneumonia where
reported,23 while others reported a 1–10% incidence of
pneumonia in IBD pts on 6-MP therapy.24 The largest series of
lung toxicity related to AZA with description of 7 cases on
AZA therapy was reported in patients undergoing renal
allograft transplant immunosuppression.25 Lung biopsies
revealed interstitial pneumonitis in 5 patients and diffuse
alveolar damage in 2 patients; 3 patients died and the other 4
improved after stopping AZA and in 2 of these patients
cyclophosphamide therapy to resolve completely this side
effect was needed. Thus, a history of recent purine analog
use in the presence of diffuse pulmonary infiltrates, fever,
hypoxia and respiratory failure should prompt cessation of
the drug to prevent progression of the symptoms and
catastrophic outcome.
2.3. Methotrexate
Methotrexate may be useful in the treatment of Crohn's
disease, but it may cause a lung drug reaction that, in some
cases, is lethal.26 The main symptoms are increasing
dyspnea, cough and fever. Hypoxemia and tachypnea are
always present and chest radiograms reveal a diffuse
interstitial lung disease or a “mixed” lung infiltration
(interstitial and alveolar) localized to the lower portions of
the lung. Lung functional tests show a restrictive picture
with altered lung diffusion. Methotrexate may also cause
fungal infections of the lungs.27,28 Thus, in patients with a
history of respiratory disease or current respiratory symp-
toms, lung function tests with determination of the diffusing
capacity for carbon monoxide are recommended during the
therapy with this drug.29
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These new therapeutic approaches have become widespread
in recent years, and serious side effects may occur,
necessitating careful monitoring of therapy.30,31 An impor-
tant caveat is the possible reactivation of tuberculosis in
patients undergoing such treatments (most for IBD and
rheumatoid arthritis),32 and before prescribing the drug
physicians should screen patients for latent tuberculosis
infection or disease.33 However, the possibility of tubercu-
losis reactivation despite a negative screening should always
be considered.34
Moreover, the use of biological therapy has been
associated with Pneumocystis carinii pneumonia,35 as well
as with other pulmonary infections (coccidiomycosis, histo-
plasmosis, listeriosis and aspergillosis),36,37 especially in
older patients.38 Although infective complications are the
most feared after the use of biological agents, these may
induce other uncommon effects on the lung, such as
eosinophilic pneumonia,39 acute respiratory distress syn-
drome,40 diffuse alveolar hemorrhage,41 and interstitial
pneumonitis.42
2.5. Cyclosporine
Cyclosporine is a potent immunosuppressive medication also
useful in severe cases of IBD.43 Apart from unusual effects
due to aspiration of the drug,44 most of the effects on the
lungs are due to opportunistic infections (Pneumocystis
carinii).45,46
3. IBD-related lung pathology
3.1. Fistulas
Up to 50% of patients with CD are affected by fistulas, which
is a major problem given the considerable morbidity
associated with this complication.47,48 Most of the fistulas
appear in the perineal area 49; to date, only a few reports
(mostly as single cases) are available on the occurrence of
enteric-pulmonary fistulas in IBD, such as colo-bronchial,50
ileo-bronchial,51 and esophago-bronchial52,53 fistulas. Lung
fistulas should be considered in patients with CD affected by
frequent episodes of pneumonitis or in presence of intestinal
anaerobic flora in the sputum.54
3.2. Granulomatous diseases
Crohn's disease and sarcoidosis are chronic inflammatory
barrier diseases that share several clinical and immunolog-
ical features, including the occurrence of granulomas. Since
these two conditions also share common susceptibility loci,55
it is not surprising that these two diseases may simulta-
neously appear in the same patient, with pulmonary
involvement,56 even though this happens quite rarely
(there are about 50 such reports in literature) and the two
diseases usually follow an independent clinical course.57
However, it is thought that due to the similarities between
these two entities, a differential diagnosis is difficult and
sometimes impossible.58Even though CD has been described associated to
Wegener's granulomatosis,59 the genetic background be-
tween the two conditions seems different.60
3.3. Autoimmune disorders
Among the EIMs of IBD, the vasculitides may be accounted
very rarely,61 with sporadic reports of UC complicated by
lung vasculitis,62 and of CD associated to Wegener's
granulomatosis.59 However, since the paucity of reports, it
is still unclear whether there is an actual association or
whether these conditions happens by chance in the same
individual.
3.4. Thromboembolic pathologies
Pulmonary embolism (PE) should be always considered in IBD
patients with breathing difficulties,63 since these patients
have an increased risk of vascular complications.64,65 The
most important of these complications are arterial and
venous thromboembolism, which represent a significant
cause of morbidity and mortality in IBD patients,66 and are
higher in patients younger than 50.67 IBD-related PE was
described, for the first time, by Bargen et al more than
70 years ago 68; since then, arterial and venous embolisms
have been reported with a percentage of 1–8%,69 with a
mortality in large series higher than 25%.70 Interestingly,
about 80% of IBD patients has active disease when PE
occurs,71 and the incidence of deep venous thrombosis (DVT)
or PE has been calculated at 40/10,000 persons year for CD
and 50/10,000 persons year for UC.69
The hypercoagulability state documented in IBD patients
has led to the research of risk factors; among these there is
an association between hyperhomocysteinemia and a history
of arterial thrombosis in IBD patients, and a high prevalence
of factor V Leiden in IBD patients with a history of venous
thrombosis.72,73 In the majority of IBD patients with previous
thromboembolic complications, at least one prothrombotic
risk factor is usually detected.74
3.5. Airway diseases
Infrequently, in IBD patients developing new, persistent and
unexplained symptoms of respiratory disease, particularly
chronic productive cough, the presence of bronchiectasies
may be demonstrated.75 Small airway disease, such as
bronchiolitis, has also been reported in these patients.76
An association between airways disease and IBD, particularly
non-asthmatic airways disease with productive cough77
seems to be present; moreover, the finding of asthma as
the most common comorbidity increased in CD patients
compared with the general population is novel,78 and
probably merits further investigation.
4. Diagnostic techniques in lung disorders
associated to IBD
The main diagnostic techniques are summarized in Table 1.79
Chest X-ray with diffuse patchy interstitial infiltrates may be
suggestive for infectious or drug-related lung disease as
Table 1 Diagnostic techniques in lung disorders associated to IBD (adapted from Ref. 75).
Diagnostic
examination
Bacterial
pneumonia
Drug-related
pneumonia
Opportunistic
infection pneumonia
Granulomatous lung
disorders
Pulmonary embolism
Chest X-ray Lobe
infiltrates
Aspecific
infiltrates in
upper and
lower lobes
Lobe infiltrates Patchy opacities and
increased mediastinal
shadow
Normal
Chest computed
tomography
(CT)
“Ground-glass”
opacities in
upper and
lower lobes
Patchy opacities Bilateral lung infiltrates and
hilar lymphadenopathies
Filling defects in the main,
segmental and lobular
branches of the pulmonary
arteries
Bronchoalveolar
lavage (BAL)
Increased
percentage
of
neutrophils
in BAL
Increased
percentage of
eosinophils in
BAL
Opportunistic agent
evident in BAL
Sputum Search
bacterial
agent in 3
samples
Polymerase chain
reaction (PCR) for
Pneumocystis in oral
washes
Histology by
bronchoscopy
Granulomas, macrophages
in alveolar spaces,
neutrophilic infiltrates in
blood capillaries
387Lung pathology and IBDopacities are present in both lower lobes.21 A drug-related
lung disorder may be confirmed by a chest computed
tomography (CT) with evidence of “ground-glass” opacities
(localized in the upper lobes or at the lung bases bilateral-
ly).21,80 “Ground-glass” opacities are defined as an increased
attenuation of the lung with preserved bronchial and
vascular margins in contrast to “consolidation”, where a
“blurring” of the bronchiolar and vascular margins is
evident.80 The differential diagnosis of “ground-glass”
opacities is extremely broad and only broncoscopy with
bronchoalveolar lavage (BAL) can allow the final diagnosis,81
since it can distinguish between pulmonary alveolar protei-
nosis, diffuse alveolar hemorrhage, malignant tumours and a
variety of opportunistic infections.80
BAL is often complementary to histopathology.82 The
cellular material of BAL derives from small airways and near
1 million alveoli.80 Typically, 85 to 93% of all BAL cells are
macrophages, 10% are lymphocytes and less than 2% are
neutrophils and eosinophils.80 In case of diffuse alveolar
damage, BAL neutrophil cells are markedly increased, while
a percentage more than 25% of BAL eosinophil cells is
suggestive for idiopathic acute eosinophilic pneumonia that
may be a clinical sign of drug-related lung disease.80 In case
of fungal infection (such as Histoplasma, Coccidioides, and
Aspergillus), a serologic test with beta-O-glucan or galacto-
mannan has a negative predictive value of up to 99%.83
Chest CT with intravenous administration of contrast
medium permits to evidence the presence of filling defects in
the main, segmental and lobular branches of the pulmonary
arteries and these radiological signs are suggestive for
pulmonary embolism.84
Oral washes have high specificity and sensitivity, and are
non invasive procedures for the detection of Pneumocystiscolonization; the use of molecular techniques (PCR) may be
used in the general population, particularly in patients
undergoing immunosuppressive therapies.85 Oral washes to
perform PCR for Pneumocystis in IBD patients may identify
the subjects that should undergo prophylaxis for this
infection.86
5. Conclusions
The involvement of the respiratory system is a relatively rare
but sometimes potentially harmful EIM of IBD. Since lung
involvement is relatively rare, all those dealing with IBD
patients must be aware of this possibility, to avoid further
complications and morbidity in the patients, and to
recognize a prompt treatment for these events.
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